ATLANTA, GA, MiRus raises $65 million for expansion of rhenium-based medical devices.
MiRus LLC, a commercial stage life sciences company, has completed a highly oversubscribed funding round for growth of its spine and extremity portfolios and development of structural heart disease solutions using its proprietary Rhenium-based alloys (MoReĀ®). The round was led by Mammoth Scientific and multi-generational family offices who have supported MiRus from its inception.
MiRus is a life sciences company that has developed and is commercializing proprietary novel biomaterials, implants and procedural solutions for the treatment of spine, orthopaedic and structural heart disease.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
